Kiniksa Pharmaceuticals International, plc
Rank #28HypergrowthKNSA · Nasdaq · Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) — Rank #28 by gross profitability (GP/assets 0.73) · ROE 9.7% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001730430 · all metrics point-in-time as of the filing date.
About
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Show moreShow less
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- kiniksa.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$5.77B
P/E (annual)
100.0
P/S (annual)
8.5
P/B
9.5
P/OCF (annual)
41.8
Shareholder Yield
-10.6%
Employees
366
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
18.3%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 10.6% — per-share value needs a total required return of 28.8% once share-count change is priced in.
vs. own 6-year median revenue growth: 56.6%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
13.4%
r = 10% (base)
18.3%
r = 12%
22.5%
Net debt / market cap: -7.9%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.73
Primary signal (Novy-Marx).
3rd of 9 SIC 2834 peers
Return on equity
9.7%
Gross margin
88.5%
2nd of 9 SIC 2834 peers
Revenue growth (YoY)
60.1%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
45.5%
Revenue CAGR (5Y)
—
Earnings CAGR (3Y)
-31.5%
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.36
2nd of 9 SIC 2834 peers (best = lowest)
Current ratio
3.79×
3rd of 9 SIC 2834 peers
Quick ratio
3.14×
Net cash
$468.09M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$136.42M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.31
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
5.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
7 / 9
Fundamental-strength score (0-9).